Pheochromocytoma - update on disease management

Therapeutic Advances in Endocrinology and Metabolism

Volumn 3, Issue 1, 2012, Pages 11-26

  Därr, Roland ^a   Lenders, Jacques W M ^b   Hofbauer, Lorenz C ^c   Bornstein, Stefan R ^c   Naumann, Bernd ^d   Eisenhofer, Graeme ^e  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Medicine III ^*  (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Institute of Clinical Chemistry and Pathobiochemistry   (Germany)

Author keywords

clinical presentation; diagnosis; follow up; genetic testing; management; paraganglioma; pheochromocytoma; treatment

Indexed keywords

ATENOLOL; ATRACURIUM; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CYCLOPHOSPHAMIDE; DACARBAZINE; DESFLURANE; DILTIAZEM; DOXAZOSIN; ENFLURANE; ESMOLOL; LABETALOL; MAGNESIUM SULFATE; METADRENALIN; METIROSINE; METOPROLOL; NIFEDIPINE; PANCURONIUM; PHENOXYBENZAMINE; PHOSPHOPROTEIN PHOSPHATASE 2A; SEVOFLURANE; TEMOZOLOMIDE; VECURONIUM; VINCRISTINE;

ADRENALECTOMY; ADRENALIN BLOOD LEVEL; ADRENALIN URINE LEVEL; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CATECHOLAMINE RELEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DRUG CONTRAINDICATION; GENE MUTATION; GENERAL ANESTHESIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INCIDENTALOMA; LAPAROSCOPIC SURGERY; MAX GENE; NF1 GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREGNANCY; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; SAFETY; SDH GENE; SDHB GENE; SDHD GENE; SENSITIVITY AND SPECIFICITY; TACHYCARDIA; TREATMENT RESPONSE; TUMOR LOCALIZATION; URINALYSIS;

EID: 84857864273     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018812437356     Document Type: Article

References (163)

1. Ahlawat S.K. Jain S. Kumari S. Varma S. Sharma B.K. (1999) Pheochromocytoma Associated with Pregnancy: Case Report and Review of the Literature. Obstet Gynecol Surv 54: 728–737.
2. Amar L. Servais A. Gimenez-Roqueplo A.P. Zinzindohoue F. Chatellier G. Plouin P.F. (2005 a) Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting Paraganglioma. J Clin Endocrinol Metab 90: 2110–2116.
3. Amar L. Bertherat J. Baudin E. Ajzenberg C. Bressac-De Paillerets B. Chabre O. et al. (2005 b) Genetic Testing in Pheochromocytoma or Functional Paraganglioma. J Clin Oncol 23: 8812–8818.
4. Anderson G.H. Jr. Blakeman N. Streeten D.H. (1994) The Effect of Age on Prevalence of Secondary Forms of Hypertension in 4429 Consecutively Referred Patients. J Hypertens 12: 609–615.
5. Astuti D. Latif F. Dallol A. Dahia P.L. Douglas F. George E. et al. (2001) Gene Mutations in the Succinate Dehydrogenase Subunit Sdhb Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma. Am J Hum Genet 69: 49–54.
6. Augoustides J.G. Abrams M. Berkowitz D. Fraker D. (2004) Vasopressin for Hemodynamic Rescue in Catecholamine-Resistant Vasoplegic Shock after Resection of Massive Pheochromocytoma. Anesthesiology 101: 1022–1024.
7. Averbuch S.D. Steakley C.S. Young R.C. Gelmann E.P. Goldstein D.S. Stull R. et al. (1988) Malignant Pheochromocytoma: Effective Treatment with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine. Ann Intern Med 109: 267–273.
8. Baysal B.E. Ferrell R.E. Willett-Brozick J.E. Lawrence E.C. Myssiorek D. Bosch A. et al. (2000) Mutations in Sdhd, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma. Science 287: 848–851.
9. Bergman S.M. Sears H.F. Javadpour N. Keiser H.R. (1978) Postoperative Management of Patients with Pheochromocytoma. J Urol 120: 109–112.
10. Bhatia K.S. Ismail M.M. Sahdev A. Rockall A.G. Hogarth K. Canizales A. et al. (2008) 123i-Metaiodobenzylguanidine (Mibg) Scintigraphy for the Detection of Adrenal and Extra-Adrenal Phaeochromocytomas: Ct and Mri Correlation. Clin Endocrinol (Oxf) 69: 181–188.
11. Boutros A.R. Bravo E.L. Zanettin G. Straffon R.A. (1990) Perioperative Management of 63 Patients with Pheochromocytoma. Cleve Clin J Med 57: 613–617.
12. Brain K.L. Kay J. Shine B. (2006) Measurement of Urinary Metanephrines to Screen for Pheochromocytoma in an Unselected Hospital Referral Population. Clin Chem 52: 2060–2064.
13. Brauckhoff M. Gimm O. Brauckhoff K. Dralle H. (2004) Repeat Adrenocortical-Sparing Adrenalectomy for Recurrent Hereditary Pheochromocytoma. Surg Today 34: 251–255.
14. Bravo E.L. (1994) Evolving Concepts in the Pathophysiology, Diagnosis, and Treatment of Pheochromocytoma. Endocr Rev 15: 356–368.
15. Bravo E.L. Tagle R. (2003) Pheochromocytoma: State-of-the-Art and Future Prospects. Endocr Rev 24: 539–553.
16. Briggs R.S. Birtwell A.J. Pohl J.E. (1978) Hypertensive Response to Labetalol in Phaeochromocytoma. Lancet 1: 1045–1046.
17. Brouwers F.M. Eisenhofer G. Tao J.J. Kant J.A. Adams K.T. Linehan W.M. et al. (2006) High Frequency of Sdhb Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. J Clin Endocrinol Metab 91: 4505–4509.
18. Brunt L.M. (2001) Phaeochromocytoma in Pregnancy. Br J Surg 88: 481–483.
19. Bryant J. Farmer J. Kessler L.J. Townsend R.R. Nathanson K.L. (2003) Pheochromocytoma: The Expanding Genetic Differential Diagnosis. J Natl Cancer Inst 95: 1196–1204.
20. Burnichon N. Briere J.J. Libe R. Vescovo L. Riviere J. Tissier F. et al. (2010) Sdha Is a Tumor Suppressor Gene Causing Paraganglioma. Hum Mol Genet 19: 3011–3020.
21. Burnichon N. Vescovo L. Amar L. Libe R. de Reynies A. Venisse A. et al. (2011) Integrative Genomic Analysis Reveals Somatic Mutations in Pheochromocytoma and Paraganglioma. Hum Mol Genet 20: 3974–3985.
22. Comino-Mendez I. Gracia-Aznarez F.J. Schiavi F. Landa I. Leandro-Garcia L.J. Leton R. et al. (2011) Exome Sequencing Identifies Max Mutations as a Cause of Hereditary Pheochromocytoma. Nat Genet 43: 663–667.
23. Costello G.T. Moorthy S.S. Vane D.W. Dierdorf S.F. (1988) Hypoglycemia Following Bilateral Adrenalectomy for Pheochromocytoma. Crit Care Med 16: 562–563.
24. Darr R. Eisenhofer G. Kotzerke J. Zophel K. Stroszczynski C. Deinum J. et al. (2011) Is There Still a Place for Adrenal Venous Sampling in the Diagnostic Localization of Pheochromocytoma? Endocrine 40: 75–79.
25. Decoulx M. Wemeau J.L. Racadot-Leroy N. Grimbert I. Proye C. Plane C. (1987) [Alpha-Methyl-Paratyrosine in the Treatment of Malignant Pheochromocytoma]. Rev Med Interne 8: 383–388.
26. Demeure M.J. Carlsen B. Traul D. Budney C. Lalande B. Lipinski A. et al. (1998) Laparoscopic Removal of a Right Adrenal Pheochromocytoma in a Pregnant Woman. J Laparoendosc Adv Surg Tech A 8: 315–319.
27. Desmonts J.M. Marty J. (1984) Anaesthetic Management of Patients with Phaeochromocytoma. Br J Anaesth 56: 781–789.
28. Douglas W.W. Rubin R.P. (1963) The Mechanism of Catecholamine Release from the Adrenal Medulla and the Role of Calcium in Stimulus-Secretion Coupling. J Physiol 167: 288–310.
29. Eisenhofer G. Bornstein S.R. Brouwers F.M. Cheung N.K. Dahia P.L. de Krijger R.R. et al. (2004) Malignant Pheochromocytoma: Current Status and Initiatives for Future Progress. Endocr Relat Cancer 11: 423–436.
30. Eisenhofer G. Pacak K. Huynh T.T. Qin N. Bratslavsky G. Linehan W.M. et al. (2010) Catecholamine Metabolomic and Secretory Phenotypes in Phaeochromocytoma. Endocr Relat Cancer 18: 97–111.
31. Eisenhofer G. Timmers H.J. Lenders J.W. Bornstein S.R. Tiebel O. Mannelli M. et al. (2011 a) Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. J Clin Endocrinol Metab 96: 375–384.
32. Eisenhofer G. Lenders J.W. Timmers H. Mannelli M. Grebe S.K. Hofbauer L.C. et al. (2011 b) Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clin Chem 57: 411–420.
33. Eisenhofer G. Lenders J.W. Siegert G. Bornstein S. Friberg P. Milosevic D. Mannelli M. Linehan W.M. Adams K. Timmers H. Pacak K. (2011 c) Plasma Methoxytyramine: A Novel Biomarker of Metastatic Pheochromocytoma and Paraganglioma in Relation to Established Risk Factors of Tumor Size, Location and Sdhb Mutation Status. Eur J Cancer: in press.
34. Engelman K. (1977) Phaeochromocytoma. Clin Endocrinol Metab 6: 769–797.
35. Fernandez-Cruz L. Taura P. Saenz A. Benarroch G. Sabater L. (1996) Laparoscopic Approach to Pheochromocytoma: Hemodynamic Changes and Catecholamine Secretion. World J Surg 20: 762-768; discussion 768.
36. Francis I.R. Korobkin M. (1996) Pheochromocytoma. Radiol Clin North Am 34: 1101–1112.
37. Gencarelli P.J. Roizen M.F. Miller R.D. Joyce J. Hunt T.K. Tyrrell J.B. (1981) Org Nc 45 (Norcuron) and Pheochromocytoma: A Report of Three Cases. Anesthesiology 55: 690–693.
38. Gill I.S. (2001) The Case for Laparoscopic Adrenalectomy. J Urol 166: 429–436.
39. Gimenez-Roqueplo A.P. Favier J. Rustin P. Rieubland C. Crespin M. Nau V. et al. (2003) Mutations in the Sdhb Gene Are Associated with Extra-Adrenal and/or Malignant Phaeochromocytomas. Cancer Res 63: 5615–5621.
40. Gray R.J. (1988) Managing Critically Ill Patients with Esmolol. An Ultra Short-Acting Beta-Adrenergic Blocker. Chest 93: 398–403.
41. Griffen W.O. Jr. Dilts P.V. Jr. Roddick J.W. Jr. (1969) Non-Obstetric Surgery During Pregnancy. Curr Probl Surg: 1–56.
42. Grodski S. Jung C. Kertes P. Davies M. Banting S. (2006) Phaeochromocytoma in Pregnancy. Intern Med J 36: 604–606.
43. Grossman A. Pacak K. Sawka A. Lenders J.W. Harlander D. Peaston R.T. et al. (2006) Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus? Ann N Y Acad Sci 1073: 332–347.
44. Harper M.A. Murnaghan G.A. Kennedy L. Hadden D.R. Atkinson A.B. (1989) Phaeochromocytoma in Pregnancy. Five Cases and a Review of the Literature. Br J Obstet Gynaecol 96: 594–606.
45. Hoegerle S. Nitzsche E. Altehoefer C. Ghanem N. Manz T. Brink I. et al. (2002) Pheochromocytomas: Detection with 18f Dopa Whole Body Pet–Initial Results. Radiology 222: 507–512.
46. Hull C.J. (1986) Phaeochromocytoma. Diagnosis, Preoperative Preparation and Anaesthetic Management. Br J Anaesth 58: 1453–1468.
47. Ilias I. Yu J. Carrasquillo J.A. Chen C.C. Eisenhofer G. Whatley M. et al. (2003) Superiority of 6-[18f]-Fluorodopamine Positron Emission Tomography Versus [131i]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma. J Clin Endocrinol Metab 88: 4083–4087.
48. Ilias I. Pacak K. (2004) Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. J Clin Endocrinol Metab 89: 479–491.
49. Inabnet W.B. Caragliano P. Pertsemlidis D. (2000) Pheochromocytoma: Inherited Associations, Bilaterality, and Cortex Preservation. Surgery 128: 1007-1011;discussion 1011–1002.
50. Isles C.G. Johnson J.K. (1983) Phaeochromocytoma and Diabetes Mellitus: Further Evidence That Alpha 2 Receptors Inhibit Insulin Release in Man. Clin Endocrinol (Oxf) 18: 37–41.
51. James M.F. Huddle K.R. Owen A.D. van der Veen B.W. (1988) Use of Magnesium Sulphate in the Anaesthetic Management of Phaeochromocytoma in Pregnancy. Can J Anaesth 35: 178–182.
52. James M.F. (1989) Use of Magnesium Sulphate in the Anaesthetic Management of Phaeochromocytoma: A Review of 17 Anaesthetics. Br J Anaesth 62: 616–623.
53. Janeczko G.F. Ivankovich A.D. Glisson S.N. Heyman H.J. El-Etr A.A. Albrecht R.F. (1977) Enflurane Anesthesia for Surgical Removal of Pheochromocytoma. Anesth Analg 56: 62–67.
54. Janetschek G. Finkenstedt G. Gasser R. Waibel U.G. Peschel R. Bartsch G. et al. (1998) Laparoscopic Surgery for Pheochromocytoma: Adrenalectomy, Partial Resection, Excision of Paragangliomas. J Urol 160: 330–334.
55. Jaroszewski D.E. Tessier D.J. Schlinkert R.T. Grant C.S. Thompson G.B. van Heerden J.A. et al. (2003) Laparoscopic Adrenalectomy for Pheochromocytoma. Mayo Clin Proc 78: 1501–1504.
56. John H. Ziegler W.H. Hauri D. Jaeger P. (1999) Pheochromocytomas: Can Malignant Potential Be Predicted? Urology 53: 679–683.
57. Jones R.M. Hill A.B. (1981) Severe Hypertension Associated with Pancuronium in a Patient with a Phaeochromocytoma. Can Anaesth Soc J 28: 394–396.
58. Joshua A.M. Ezzat S. Asa S.L. Evans A. Broom R. Freeman M. et al. (2009) Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma. J Clin Endocrinol Metab 94: 5–9.
59. Joyce J.T. Roizen M.F. Eger E.I. 2nd. (1983) Effect of Thiopental Induction on Sympathetic Activity. Anesthesiology 59: 19–22.
60. Kinney M.A. Warner M.E. Vanheerden J.A. Horlocker T.T. Young W.F. Jr. Schroeder D.R. et al. (2000) Perianesthetic Risks and Outcomes of Pheochromocytoma and Paraganglioma Resection. Anesth Analg 91: 1118–1123.
61. Kinney M.A. Narr B.J. Warner M.A. (2002) Perioperative Management of Pheochromocytoma. J Cardiothorac Vasc Anesth 16: 359–369.
62. Kocak S. Aydintug S. Canakci N. (2002) Alpha Blockade in Preoperative Preparation of Patients with Pheochromocytomas. Int Surg 87: 191–194.
63. Korpershoek E. Favier J. Gaal J. Burnichon N. van Gessel B. Oudijk L. et al. (2011) Sdha Immunohistochemistry Detects Germline Sdha Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. J Clin Endocrinol Metab 96: E1472–E1476
64. Kroiss A. Putzer D. Uprimny C. Decristoforo C. Gabriel M. Santner W. et al. (2011) Functional Imaging in Phaeochromocytoma and Neuroblastoma with 68ga-Dota-Tyr 3-Octreotide Positron Emission Tomography and 123i-Metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 38: 865–873.
65. Kunst H.P. Rutten M.H. de Monnink J.P. Hoefsloot L.H. Timmers H.J. Marres H.A. et al. (2011) Sdhaf 2 (Pgl2-Sdh5) and Hereditary Head and Neck Paraganglioma. Clin Cancer Res 17: 247–254.
66. La Batide-Alanore A. Chatellier G. Plouin P.F. (2003) Diabetes as a Marker of Pheochromocytoma in Hypertensive Patients. J Hypertens 21: 1703–1707.
67. Lagerstedt S.A. O'kane D.J. Singh R.J. (2004) Measurement of Plasma Free Metanephrine and Normetanephrine by Liquid Chromatography-Tandem Mass Spectrometry for Diagnosis of Pheochromocytoma. Clin Chem 50: 603–611.
68. Lairmore T.C. Ball D.W. Baylin S.B. Wells S.A. Jr. (1993) Management of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 Syndromes. Ann Surg 217: 595-601; discussion 601–593.
69. Lee J.E. Curley S.A. Gagel R.F. Evans D.B. Hickey R.C. (1996) Cortical-Sparing Adrenalectomy for Patients with Bilateral Pheochromocytoma. Surgery 120: 1064-1070; discussion 1070–1061.
70. Lenders J.W. Pacak K. Walther M.M. Linehan W.M. Mannelli M. Friberg P. et al. (2002) Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best? Jama 287: 1427–1434.
71. Lenders J.W. Eisenhofer G. Mannelli M. Pacak K. (2005) Phaeochromocytoma. Lancet 366: 665–675.
72. Lenders J. (2011) Review Topic: Endocrine Disorders in Pregnancy Phaeochromocytoma and Pregnancy:A Deceptive Connection. Eur J Endocrinol: in press.
73. Lentschener C. Gaujoux S. Tesniere A. Dousset B. (2011) Point of Controversy: Perioperative Care of Patients Undergoing Pheochromocytoma Removal-Time for a Reappraisal? Eur J Endocrinol 165: 365–373.
74. Liao W.B. Liu C.F. Chiang C.W. Kung C.T. Lee C.W. (2000) Cardiovascular Manifestations of Pheochromocytoma. Am J Emerg Med 18: 622–625.
75. Lippmann M. Ford M. Lee C. Ginsburg R. Foran W. Raum W. et al. (1994) Use of Desflurane During Resection of Phaeochromocytoma. Br J Anaesth 72: 707–709.
76. Manger W.M. Gifford R.W. (1996) Clinical and Experimental Pheochromocytoma. Blackwell Science.
77. Manger W.M. (2006) An Overview of Pheochromocytoma: History, Current Concepts, Vagaries, and Diagnostic Challenges. Ann N Y Acad Sci 1073: 1–20.
78. Manger W.M. (2009) The Protean Manifestations of Pheochromocytoma. Horm Metab Res 41: 658–663.
79. Mannelli M. Bemporad D. (2002) Diagnosis and Management of Pheochromocytoma During Pregnancy. J Endocrinol Invest 25: 567–571.
80. Mannelli M. (2006) Management and Treatment of Pheochromocytomas and Paragangliomas. Ann N Y Acad Sci 1073: 405–416.
81. Mansmann G. Lau J. Balk E. Rothberg M. Miyachi Y. Bornstein S.R. (2004) The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management. Endocr Rev 25: 309–340.
82. Mantero F. Terzolo M. Arnaldi G. Osella G. Masini A.M. Ali A. et al. (2000) A Survey on Adrenal Incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85: 637–644.
83. Martiniova L. Lu J. Chiang J. Bernardo M. Lonser R. Zhuang Z. et al. (2011) Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes Pheo in a Mpc Cell and Mouse Model to Conventional Chemotherapy. PloS ONE 6: e14678.
84. Maurea S. Cuocolo A. Reynolds J.C. Tumeh S.S. Begley M.G. Linehan W.M. et al. (1993) Iodine-131-Metaiodobenzylguanidine Scintigraphy in Preoperative and Postoperative Evaluation of Paragangliomas: Comparison with Ct and Mri. J Nucl Med 34: 173–179.
85. Maurea S. Cuocolo A. Reynolds J.C. Neumann R.D. Salvatore M. (1996) Diagnostic Imaging in Patients with Paragangliomas. Computed Tomography, Magnetic Resonance and Mibg Scintigraphy Comparison. Q J Nucl Med 40: 365–371.
86. Mcneil A.R. Blok B.H. Koelmeyer T.D. Burke M.P. Hilton J.M. (2000) Phaeochromocytomas Discovered During Coronial Autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 30: 648–652.
87. Meeke R.I. O'keeffe J.D. Gaffney J.D. (1985) Phaeochromocytoma Removal and Postoperative Hypoglycaemia. Anaesthesia 40: 1093–1096.
88. Minno A.M. Bennett W.A. Kvale W.F. (1954) Pheochromocytoma; a Study of 15 Cases Diagnosed at Autopsy. N Engl J Med 251: 959–965.
89. Mishra A.K. Agarwal G. Kapoor A. Agarwal A. Bhatia E. Mishra S.K. (2000) Catecholamine Cardiomyopathy in Bilateral Malignant Pheochromocytoma: Successful Reversal after Surgery. Int J Cardiol 76: 89–90.
90. Miskulin J. Shulkin B.L. Doherty G.M. Sisson J.C. Burney R.E. Gauger P.G. (2003) Is Preoperative Iodine 123 Meta-Iodobenzylguanidine Scintigraphy Routinely Necessary before Initial Adrenalectomy for Pheochromocytoma? Surgery 134: 918-922; discussion 922–913.
91. Molitch M.E. (1992) Endocrine Emergencies in Pregnancy. Baillieres Clin Endocrinol Metab 6: 167–191.
92. Mullins F. O'shea P. Fitzgerald R. Tormey W. (2011) Enzyme-Linked Immunoassay for Plasma-Free Metanephrines in the Biochemical Diagnosis of Phaeochromocytoma in Adults Is Not Ideal. Clin Chem Lab Med: in press.
93. Neumann H.P. Berger D.P. Sigmund G. Blum U. Schmidt D. Parmer R.J. et al. (1993) Pheochromocytomas, Multiple Endocrine Neoplasia Type 2, and Von Hippel-Lindau Disease. N Engl J Med 329: 1531–1538.
94. Neumann H.P. Reincke M. Bender B.U. Elsner R. Janetschek G. (1999) Preserved Adrenocortical Function after Laparoscopic Bilateral Adrenal Sparing Surgery for Hereditary Pheochromocytoma. J Clin Endocrinol Metab 84: 2608–2610.
95. Neumann H.P. Bausch B. Mcwhinney S.R. Bender B.U. Gimm O. Franke G. et al. (2002) Germ-Line Mutations in Nonsyndromic Pheochromocytoma. N Engl J Med 346: 1459–1466.
96. Neumann H.P. Pawlu C. Peczkowska M. Bausch B. Mcwhinney S.R. Muresan M. et al. (2004) Distinct Clinical Features of Paraganglioma Syndromes Associated with Sdhb and Sdhd Gene Mutations. Jama 292: 943–951.
97. Niemann S. Muller U. (2000) Mutations in Sdhc Cause Autosomal Dominant Paraganglioma, Type 3. Nat Genet 26: 268–270.
98. Nonaka K. Makuuchi H. Naruse Y. Kobayashi T. Goto M. (2000) Surgical Excision of Malignant Pheochromocytoma in the Left Atrium. Jpn J Thorac Cardiovasc Surg 48: 126–128.
99. Oishi S. Sato T. (1994) Pheochromocytoma in Pregnancy: A Review of the Japanese Literature. Endocr J 41: 219–225.
100. Ostenson C.G. Cattaneo A.G. Doxey J.C. Efendic S. (1989) Alpha-Adrenoceptors and Insulin Release from Pancreatic Islets of Normal and Diabetic Rats. Am J Physiol 257: E439–E443
101. Pacak K. Linehan W.M. Eisenhofer G. Walther M.M. Goldstein D.S. (2001 a) Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Ann Intern Med 134: 315–329.
102. Pacak K. Eisenhofer G. Carrasquillo J.A. Chen C.C. Li S.T. Goldstein D.S. (2001 b) 6-[18f]Fluorodopamine Positron Emission Tomographic (Pet) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension 38: 6–8.
103. Pacak K. Eisenhofer G. Goldstein D.S. (2004) Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography. Endocr Rev 25: 568–580.
104. Pacak K. Eisenhofer G. Lenders J.W.M. (2007 a) Pheochromocytoma: Diagnosis, Localization, and Treatment. Blackwell Pub.
105. Pacak K. Eisenhofer G. Ahlman H. Bornstein S.R. Gimenez-Roqueplo A.P. Grossman A.B. et al. (2007 b) Pheochromocytoma: Recommendations for Clinical Practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 3: 92–102.
106. Pacak K. Eisenhofer G. (2007 c) An Assessment of Biochemical Tests for the Diagnosis of Pheochromocytoma. Nat Clin Pract Endocrinol Metab 3: 744–745.
107. Pacak K. (2007 d) Preoperative Management of the Pheochromocytoma Patient. J Clin Endocrinol Metab 92: 4069–4079.
108. Peaston R.T. Lennard T.W. Lai L.C. (1996) Overnight Excretion of Urinary Catecholamines and Metabolites in the Detection of Pheochromocytoma. J Clin Endocrinol Metab 81: 1378–1384.
109. Perry R.R. Keiser H.R. Norton J.A. Wall R.T. Robertson C.N. Travis W. et al. (1990) Surgical Management of Pheochromocytoma with the Use of Metyrosine. Ann Surg 212: 621–628.
110. Pillai D. Callen S. (2010) Pilot Quality Assurance Programme for Plasma Metanephrines. Ann Clin Biochem 47: 137–142.
111. Plouin P.F. Chatellier G. Fofol I. Corvol P. (1997) Tumor Recurrence and Hypertension Persistence after Successful Pheochromocytoma Operation. Hypertension 29: 1133–1139.
112. Plouin P.F. Duclos J.M. Soppelsa F. Boublil G. Chatellier G. (2001) Factors Associated with Perioperative Morbidity and Mortality in Patients with Pheochromocytoma: Analysis of 165 Operations at a Single Center. J Clin Endocrinol Metab 86: 1480–1486.
113. Prejbisz A. Lenders J.W. Eisenhofer G. Januszewicz A. (2011) Cardiovascular Manifestations of Phaeochromocytoma. J Hypertens 29: 2049–2060.
114. Proye C. Thevenin D. Cecat P. Petillot P. Carnaille B. Verin P. et al. (1989) Exclusive Use of Calcium Channel Blockers in Preoperative and Intraoperative Control of Pheochromocytomas: Hemodynamics and Free Catecholamine Assays in Ten Consecutive Patients. Surgery 106: 1149–1154.
115. Prys-Roberts C. (2000) Phaeochromocytoma– Recent Progress in Its Management. Br J Anaesth 85: 44–57.
116. Prys-Roberts C. Farndon J.R. (2002) Efficacy and Safety of Doxazosin for Perioperative Management of Patients with Pheochromocytoma. World J Surg 26: 1037–1042.
117. Qin Y. Yao L. King E.E. Buddavarapu K. Lenci R.E. Chocron E.S. et al. (2010) Germline Mutations in Tmem 127 Confer Susceptibility to Pheochromocytoma. Nat Genet 42: 229–233.
118. Quezado Z.N. Keiser H.R. Parker M.M. (1992) Reversible Myocardial Depression after Massive Catecholamine Release from a Pheochromocytoma. Crit Care Med 20: 549–551.
119. Reach G. Thibonnier M. Chevillard C. Corvol P. Milliez P. (1980) Effect of Labetalol on Blood Pressure and Plasma Catecholamine Concentrations in Patients with Phaeochromocytoma. Br Med J 280: 1300–1301.
120. Rose B. Matthay K.K. Price D. Huberty J. Klencke B. Norton J.A. et al. (2003) High-Dose 131i-Metaiodobenzylguanidine Therapy for 12 Patients with Malignant Pheochromocytoma. Cancer 98: 239–248.
121. Russell W.J. Metcalfe I.R. Tonkin A.L. Frewin D.B. (1998) The Preoperative Management of Phaeochromocytoma. Anaesth Intensive Care 26: 196–200.
122. Schenker J.G. Granat M. (1982) Phaeochromocytoma and Pregnancy–an Updated Appraisal. Aust N Z J Obstet Gynaecol 22: 1–10.
123. Schlegel G.C. (1960) [Recklinghausen's Neurofibromatosis and Pheochromocytoma]. Schweiz Med Wochenschr 90: 31–39.
124. Schlumberger M. Gicquel C. Lumbroso J. Tenenbaum F. Comoy E. Bosq J. et al. (1992) Malignant Pheochromocytoma: Clinical, Biological, Histologic and Therapeutic Data in a Series of 20 Patients with Distant Metastases. J Endocrinol Invest 15: 631–642.
125. Schurmeyer T.H. Engeroff B. Dralle H. Von Zur Muhlen A. (1997) Cardiological Effects of Catecholamine-Secreting Tumours. Eur J Clin Invest 27: 189–195.
126. Scott H.W. Jr. Halter S.A. (1984) Oncologic Aspects of Pheochromocytoma: The Importance of Follow-Up. Surgery 96: 1061–1066.
127. Shapiro B. Copp J.E. Sisson J.C. Eyre P.L. Wallis J. Beierwaltes W.H. (1985) Iodine-131 Metaiodobenzylguanidine for the Locating of Suspected Pheochromocytoma: Experience in 400 Cases. J Nucl Med 26: 576–585.
128. Shapiro B. Sisson J.C. Shulkin B.L. Gross M.D. Zempel S. (1995) The Current Status of Meta-Iodobenzylguanidine and Related Agents for the Diagnosis of Neuro-Endocrine Tumors. Q J Nucl Med 39: 3–8.
129. Singh R.J. Eisenhofer G. (2007) High-Throughput, Automated, and Accurate Biochemical Screening for Pheochromocytoma: Are We There Yet? Clin Chem 53: 1565–1567.
130. Sisson J.C. Shapiro B. Shulkin B.L. Urba S. Zempel S. Spaulding S. (1999 a) Treatment of Malignant Pheochromocytomas with 131-I Metaiodobenzylguanidine and Chemotherapy. Am J Clin Oncol 22: 364–370.
131. Sisson J.C. Shulkin B.L. (1999 b) Nuclear Medicine Imaging of Pheochromocytoma and Neuroblastoma. Q J Nucl Med 43: 217–223.
132. Sjoerdsma A. Engelman K. Spector S. Udenfriend S. (1965) Inhibition of Catecholamine Synthesis in Man with Alpha-Methyl-Tyrosine, an Inhibitor of Tyrosine Hydroxylase. Lancet 2: 1092–1094.
133. Sprung J. O'hara J.F. Jr. Gill I.S. Abdelmalak B. Sarnaik A. Bravo E.L. (2000) Anesthetic Aspects of Laparoscopic and Open Adrenalectomy for Pheochromocytoma. Urology 55: 339–343.
134. Stoner T.R. Jr. Urbach K.F. (1968) Cardiac Arrhythmias Associated with Succinylcholine in a Patient with Pheochromocytoma. Anesthesiology 29: 1228–1229.
135. Sullivan J.M. Solomon H.S. (1975) The Diagnosis of Pheochromocytoma. Overnight Excretion of Catecholamine Metabolites. Jama 231: 618–619.
136. Sumikawa K. Amakata Y. (1977) The Pressor Effect of Droperidol on a Patient with Pheochromocytoma. Anesthesiology 46: 359–361.
137. Tauzin-Fin P. Hilbert G. Krol-Houdek M. Gosse P. Maurette P. (1999) Mydriasis and Acute Pulmonary Oedema Complicating Laparoscopic Removal of Phaechromocytoma. Anaesth Intensive Care 27: 646–649.
138. Tauzin-Fin P. Sesay M. Gosse P. Ballanger P. (2004) Effects of Perioperative Alpha 1 Block on Haemodynamic Control During Laparoscopic Surgery for Phaeochromocytoma. Br J Anaesth 92: 512–517.
139. Thompson L.D. (2002) Pheochromocytoma of the Adrenal Gland Scaled Score (Pass) to Separate Benign from Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases. Am J Surg Pathol 26: 551–566.
140. Timmers H.J. Kozupa A. Eisenhofer G. Raygada M. Adams K.T. Solis D. et al. (2007 a) Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with Succinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab 92: 779–786.
141. Timmers H.J. Kozupa A. Chen C.C. Carrasquillo J.A. Ling A. Eisenhofer G. et al. (2007 b) Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic Sdhb-Associated Pheochromocytoma and Paraganglioma. J Clin Oncol 25: 2262–2269.
142. Timmers H.J. Pacak K. Huynh T.T. Abu-Asab M. Tsokos M. Merino M.J. et al. (2008) Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the Succinate Dehydrogenase Subunit B Gene. J Clin Endocrinol Metab 93: 4826–4832.
143. Timmers H.J. Chen C.C. Carrasquillo J.A. Whatley M. Ling A. Havekes B. et al. (2009) Comparison of 18f-Fluoro-L-Dopa, 18f-Fluoro-Deoxyglucose, and 18f-Fluorodopamine Pet and 123i-Mibg Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 94: 4757–4767.
144. Tischler A.S. (2008) Pheochromocytoma and Extra-Adrenal Paraganglioma: Updates. Arch Pathol Lab Med 132: 1272–1284.
145. Tokioka H. Takahashi T. Kosogabe Y. Ohta Y. Kosaka F. (1988) Use of Diltiazem to Control Circulatory Fluctuations During Resection of a Phaeochromocytoma. Br J Anaesth 60: 582–587.
146. Trampal C. Engler H. Juhlin C. Bergstrom M. Langstrom B. (2004) Pheochromocytomas: Detection with 11c Hydroxyephedrine Pet. Radiology 230: 423–428.
147. Ulchaker J.C. Goldfarb D.A. Bravo E.L. Novick A.C. (1999) Successful Outcomes in Pheochromocytoma Surgery in the Modern Era. J Urol 161: 764–767.
148. van der Horst-Schrivers A.N. Kerstens M.N. Wolffenbuttel B.H. (2006) Preoperative Pharmacological Management of Phaeochromocytoma. Neth J Med 64: 290–295.
149. van Nederveen F.H. Gaal J. Favier J. Korpershoek E. Oldenburg R.A. de Bruyn E.M. et al. (2009) An Immunohistochemical Procedure to Detect Patients with Paraganglioma and Phaeochromocytoma with Germline Sdhb, Sdhc, or Sdhd Gene Mutations: A Retrospective and Prospective Analysis. Lancet Oncol 10: 764–771.
150. van Stratum M. Levarlet M. Lambilliotte J.P. Lignian H. de Rood M. (1983) Use of Labetalol During Anesthesia for Pheochromocytoma Removal. Acta Anaesthesiol Belg 34: 233–240.
151. Vargas H.I. Kavoussi L.R. Bartlett D.L. Wagner J.R. Venzon D.J. Fraker D.L. et al. (1997) Laparoscopic Adrenalectomy: A New Standard of Care. Urology 49: 673–678.
152. von Euler US Lishajko F. (1973) Effects of Mg2+ and Ca2+ on Noradrenaline Release and Uptake in Adrenergic Nerve Granules in Differential Media. Acta Physiol Scand 89: 415–422.
153. Walther M.M. Herring J. Choyke P.L. Linehan W.M. (2000) Laparoscopic Partial Adrenalectomy in Patients with Hereditary Forms of Pheochromocytoma. J Urol 164: 14–17.
154. Walz M.K. Peitgen K. Neumann H.P. Janssen O.E. Philipp T. Mann K. (2002) Endoscopic Treatment of Solitary, Bilateral, Multiple, and Recurrent Pheochromocytomas and Paragangliomas. World J Surg 26: 1005–1012.
155. Walz M.K. Groeben H. Alesina P.F. (2010) Single-Access Retroperitoneoscopic Adrenalectomy (Sara) Versus Conventional Retroperitoneoscopic Adrenalectomy (Cora): A Case-Control Study. World J Surg 34: 1386–1390.
156. Witteles R.M. Kaplan E.L. Roizen M.F. (2000) Safe and Cost-Effective Preoperative Preparation of Patients with Pheochromocytoma. Anesth Analg 91: 302–304.
157. Yabe R. Suenaga K. Niimura S. Itoh N. Tani M. Kunii N. et al. (1987) Treatment of Pheochromocytoma with Dilevalol. J Med 18: 147–152.
158. Yao L. Schiavi F. Cascon A. Qin Y. Inglada-Perez L. King E.E. et al. (2010) Spectrum and Prevalence of Fp/Tmem127 Gene Mutations in Pheochromocytomas and Paragangliomas. Jama 304: 2611–2619.
159. Yip L. Lee J.E. Shapiro S.E. Waguespack S.G. Sherman S.I. Hoff A.O. et al. (2004) Surgical Management of Hereditary Pheochromocytoma. J Am Coll Surg 198: 525–534; discussion 534–525.
160. Yoshida S. Hatori M. Noshiro T. Kimura N. Kokubun S. (2001) Twenty-Six-Years’ Survival with Multiple Bone Metastasis of Malignant Pheochromocytoma. Arch Orthop Trauma Surg 121: 598–600.
161. Young W.F. Jr. (1997) Pheochromocytoma: Issues in Diagnosis & Treatment. Compr Ther 23: 319–326.
162. Yumi H. (2008) Guidelines for Diagnosis, Treatment, and Use of Laparoscopy for Surgical Problems During Pregnancy: This Statement Was Reviewed and Approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (Sages), September 2007. It Was Prepared by the Sages Guidelines Committee. Surg Endosc 22: 849–861.
163. Zelinka T. Timmers H.J. Kozupa A. Chen C.C. Carrasquillo J.A. Reynolds J.C. et al. (2008) Role of Positron Emission Tomography and Bone Scintigraphy in the Evaluation of Bone Involvement in Metastatic Pheochromocytoma and Paraganglioma: Specific Implications for Succinate Dehydrogenase Enzyme Subunit B Gene Mutations. Endocr Relat Cancer 15: 311–323.